Freedom of Information request on information relating to Emerade (FOI 21/1068)
Published 27 April 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-18-october-2021/freedom-of-information-request-on-information-relating-to-emerade-foi-211068
18th October 2021
FOI 21/1068
Dear
Thank you for your email dated 20th September where you asked for information relating to Emerade.
Having checked our records, we can confirm that we do not hold any of the information you have requested. We can also confirm that the MHRA has not received any Yellow Card (UK spontaneous Adverse Drug Reaction [ADR]) reports relating to HLT (higher level term) product label issues where at least one suspect drug was Emerade. HLT is a hierarchical standard used in pharmacovigilance.
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division